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background:  The ATLANTIC trial is a randomized double blind placebo controlled trial evaluating the benefit of prehospital administration 
of ticagrelor in the treatment of ST-elevation myocardial infarction (STEMI) patients transferred for primary PCI. An interaction was found 
between morphine administration and ST-segment resolution (co-primary endpoint of the study, p=0.005), suggesting an interaction 
with the oral administration of ticagrelor. We evaluated the impact of morphine administration in the PRIVATE-ATLANTIC, a prespecified 
substudy, that was designed to assess the pharmacodynamic (PD) and pharmacokinetic (PK) effect of ticagrelor pretreatment.
methods:  Morphine administration was captured and its impact on platelet inhibition was evaluated by a centralized measure of 
vasodilator-stimulated phosphoprotein platelet reactivity index (VASP PRI) in a series of blood samples collected before angiogram (at the 
time of second load (T1)), after PCI (end of procedure (T2)), 1 hour after PCI (T3), 6 hours after the first load (T4) and the next day before 
the next study drug administration (T5). VerifyNow measurement and measure of the ticagrelor metabolite were also performed.
Results:  Our study population consisted of 37 patients of whom 22 (59.5%) were administered morphine before PCI (20 with intravenous 
morphine and 2 were under oral morphine). Morphine administration significantly delayed the PD response to ticagrelor irrespective of the 
pretreatment strategy, delaying the onset of action measured by VASP-PRI, with a significant difference at T3 (22.9% vs. 83.2%, p= 0.003) 
and T4 (10.9% vs. 37.6%, p= 0.003). This effect was even more pronounced in the pre-hospital than in the in-hospital ticagrelor group: 
28.5% vs. 82.3% at T2; p= 0.052; 15.7% vs. 69.1% at T3, p= 0.006; and 6.8% vs. 40.9% at T4; p= 0.02.
conclusion:  In STEMI patients, morphine administration delays the onset of action of ticagrelor. This observation supports the hypothesis 
of an interaction between morphine and oral P2Y12 inhibitors and may account for the neutral effect of prehospital treatment on the primary 
endpoint in ATLANTIC.
